Sinew Pharma Inc. (6634.TWO) Stock
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan.
Valuation
Financials & Margins
Valuation & Return Ratios
Ownership
About Sinew Pharma Inc.
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.
Sinew Pharma Inc. is led by CEO Kai-Min Chu, employs 57 people, headquartered in Taipei, TW, publicly traded since 2017.
Sinew Pharma Inc. (6634.TWO) stock trades at $55.40 with a market capitalization of $3.95B. The stock is valued at a negative price-to-earnings (P/E) ratio of -34.62, reflecting a net loss over the last twelve months, price-to-book of 3.81, price-to-sales of 84029.93. Over the past 52 weeks the stock has ranged between $29.05 and $85.00, and currently trades 34.8% below its 52-week high.
On profitability, Sinew Pharma Inc. generates a return on equity (ROE) of -10.85% (negative, reflecting a net loss), an operating margin of -283142.55%.
Official website: www.sinewpharma.com
Sinew Pharma Inc. (6634.TWO) — frequently asked questions
What is Sinew Pharma Inc. (6634.TWO) stock price today?
Sinew Pharma Inc. (6634.TWO) is currently trading at $55.40, down 3.99% today.
What is 6634.TWO P/E ratio?
Sinew Pharma Inc.'s P/E ratio is -34.62. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is 6634.TWO return on equity (ROE)?
Sinew Pharma Inc.'s return on equity (ROE) is -10.85%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Sinew Pharma Inc.'s market cap?
Sinew Pharma Inc. has a market capitalization of $3.95B.
Does 6634.TWO pay a dividend?
Sinew Pharma Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does 6634.TWO carry?
Sinew Pharma Inc. has a debt-to-equity ratio of 0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 6634.TWO's profit margin?
Sinew Pharma Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is 6634.TWO in?
Sinew Pharma Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 6634.TWO listed on?
Sinew Pharma Inc. trades on TWO under the ticker 6634.TWO.
What is 6634.TWO's 52-week range?
Over the last year Sinew Pharma Inc. has traded between $29.05 and $85.00.
Related Healthcare Stocks
Popular Stocks
Screens 6634.TWO currently matches
On the figures above, Sinew Pharma Inc. passes the filters for 8 of our ready-made screens, among them Low Debt Stocks, Debt Free Stocks Under $100, Debt Free Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.